Imago BioSciences, Inc. Common stock
IMGO
IMGO was delisted on the 10th of January, 2023.
106 hedge funds and large institutions have $1.05B invested in Imago BioSciences, Inc. Common stock in 2022 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 15 closing their positions.
273% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 15
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
120% more capital invested
Capital invested by funds: $478M → $1.05B (+$576M)
63% more funds holding
Funds holding: 65 → 106 (+41)
39% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $910K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$25.4M |
| 2 |
VI
Versor Investments
New York
|
+$25.1M |
| 3 |
TAL
TIG Advisors LLC
New York
|
+$24.8M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$24.4M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$127M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$59.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$37.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.4M |
| 5 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$12.8M |
IMGO Hedge Fund Activity: Q4 2022 in Review
106 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Imago BioSciences, Inc. Common stock (IMGO) for Q4 2022, worth a combined $1.05B — up 120% from $478M a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new IMGO positions and 15 closed out — a net gain of 41 holders — while 25 added to existing stakes and 18 trimmed.
The largest buyer was Frazier Life Sciences Management, adding an estimated $25.4M. The largest seller was Fidelity Investments, cutting an estimated $127M.
- 106 institutional investors held Imago BioSciences, Inc. Common stock (IMGO) as of Q4 2022, up from 65 in Q3 2022.
- Funds reported $1.05B of Imago BioSciences, Inc. Common stock stock for Q4 2022, up 120% quarter-over-quarter.
- 56 funds opened new Imago BioSciences, Inc. Common stock positions in Q4 2022 and 15 closed out, a net change of +41 holders.
- The largest Imago BioSciences, Inc. Common stock buyer in Q4 2022 was Frazier Life Sciences Management, an estimated $25.4M added.
- The largest Imago BioSciences, Inc. Common stock seller in Q4 2022 was Fidelity Investments, an estimated $127M sold.
Based on aggregated 13F filings for Q4 2022.